InhaleRx Ltd

Company Profile

• Business description

  InhaleRx Ltd is an Australian biotechnology company specialising in precision medicine delivered through inhalation. Its novel drug device combinations target the treatment of BTcP and PD to help improve the quality of life of sufferers of these diseases. The medications are being developed to be delivered via a pressurised metered dose inhaler (pMDI) in a fixed dose, providing a convenient and effective mode of administration. The company's clinical pipeline comprises IRX211, a THC-based synthetic cannabinoid derived drug (dronabinol) delivered via a pMDI in a fixed dose designed to provide rapid onset analgesia for patients suffering from acute episodic bursts of breakthrough pain; and IRX616a, for the treatment of panic disorders.

• Contact

  C/- Prime Company Compliance
  505 Little Collins Street
  Level 9
  MelbourneVIC3000
  AUS

  T: +61 386784091

  https://www.inhalerx.com.au

• Sector

  Healthcare

  Stock type

  Defensive

• Industry

  Biotechnology

  Fiscal Year End

  31 December 2025

  Employees